Cargando…
Therapy-related core binding factor acute myeloid leukemia
Therapy-related acute myeloid leukemia (t-AML) usually stems from exposure of the bone marrow to cytotoxic chemotherapy and/or radiation therapy. t-AML is usually associated with poor overall survival, but occasionally t-AML can involve favorable-risk cytogenetics, including core binding factor AML...
Autores principales: | George, Binsah, Yohannan, Binoy, Mohlere, Virginia, Gonzalez, Anneliese |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979104/ https://www.ncbi.nlm.nih.gov/pubmed/36874378 http://dx.doi.org/10.2217/ijh-2022-0004 |
Ejemplares similares
-
Mixed-Phenotype Acute Leukemia: Clinical Diagnosis and Therapeutic Strategies
por: George, Binsah S., et al.
Publicado: (2022) -
B-Lymphoid Blast Phase–Chronic Myeloid Leukemia: Current Therapeutics
por: Yohannan, Binoy, et al.
Publicado: (2022) -
Current Management of Chronic Myeloid Leukemia Myeloid Blast Phase
por: Yohanan, Binoy, et al.
Publicado: (2022) -
TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
por: George, Binsah, et al.
Publicado: (2021) -
Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia
por: Mosna, Federico, et al.
Publicado: (2016)